Cordis has announced the launch and availability of the SELUTION Sustained Limus Release (SLR) drug-eluting balloon (DEB) percutaneous transluminal angioplasty (PTA) for use in Japan.
Selution SLR DEB is designed to deliver sirolimus in a controlled, sustained manner to reduce restenosis and restore vessel function. The Selution SFA Japan clinical trial results demonstrated durable clinical outcomes in a complex patient population, including 81.5% primary patency and 93.8% of patients remaining free from reintervention through to three years.
Yoshimitsu Soga, co-principal investigator of the Selution SFA Japan clinical trial and director of cardiology at Kokura Memorial Hospital in Kitakyushu, Japan said: “I am pleased to see Selution SLR DEB now available for use in clinical practice in Japan. The three-year results from the Selution SFA Japan clinical trial demonstrate sustained efficacy and safety, supporting its role as an important treatment option for patients.”
Osamu Lida, co-principal investigator of the Selution SFA Japan clinical trial and director of the department of cardiology at Osaka International Medical & Science Center, Osaka Keisatsu Hospital in Osaka, Japan said: “Selution SLR DEB is a valuable addition to the treatment options for peripheral vascular disease. In my early clinical experience, I’ve observed strong post-procedural blood flow without evidence of downstream effects below the knee. I look forward to seeing its broader adoption in real-world clinical practice.”
“At Cordis, we recognise the impact peripheral artery disease can have on patients and their daily lives,” said George Adams, chief medical officer, Cordis. “The launch of Selution SLR DEB in Japan reflects our focus on expanding innovative treatment options that physicians may consider based on individual patient needs. We look forward to continuing to work with the medical community in Japan to support patient care.”
